Effect of Interferon beta-1-b on COVID-19 patients

Evaluation of treatment regimen containing beta-1-b interferon on the COVID-19 patients with mild and severe symptoms and comparing it with interferon-free treatment regimen

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20201001048894N1

Enrollment

Registered

2020-12-15

Start date

2020-10-22

Completion date

Unknown

Last updated

2021-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid 19. Covid 19 , Virus Identified

Interventions

Intervention 1: Intervention group: Subcutaneous administration of 250 microgram IFN beta-1-b every other day. Intervention 2: Control group: Control group will receive Covid-19 routine prescription.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Positive result of Real time PCR CT severity scoring P o2 < 93mmHg Respiratory rate more than 30 time per minute.

Exclusion criteria

Exclusion criteria: Diabetes Cardiac diseases pregnancy Malignancy Consumption of corticosteroids

Design outcomes

Primary

Measure	Time frame
CT severiity score. Timepoint: At the beginning and the end of study. Method of measurement: By CT scan.;ABG - Pao2. Timepoint: At the beginning and at the end of study. Method of measurement: ABG assay system.;D-dimer that is fibrin degradation product (FDP). Timepoint: At the beginning and at the end of study. Method of measurement: By ELISA.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAfshin Samiei

Bandare-abbas University of Medical Sciences

afshin.samiei@gmail.com+98 76 3371 0373

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026